Biosimilars Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2025

BIOSIMILARS MARKET
Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2017-2025
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Biosimilars Market Overview
Biosimilars are biological medical products which are the identical copies of the original
products. Biosimilars are also termed as subsequent entry biologic or follow-on biologic.
Biosimilars are expected to possess active properties, similar to that of officially approved
original product at present. Biosimilars can be manufactured only when the patent for the
original innovator product expires. Biologics or biosimilars are sensitive to changes in
manufacturing process due to the higher molecular complexity. In 2010, The Food and Drug
Administration (FDA) has gained the authority to approve biosimilars as a part of Patient
Protection and Affordable Care Act. The approval process is based on thorough demonstration
of similarity and comparability with the existing approved product. Biosimilars are generally
derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic
engineering processes including controlled gene expression and recombinant DNA technology.
Request Sample Copy of the Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/750
Patent expiry of blockbuster drugs and increasing government initiatives for biosimilars
promotion drives the growth of biosimilars market
The key factors driving the growth of biosimilars market are the increasing demand due to their
cost-effectiveness, rising geriatric population, growing pressure to curtail healthcare
expenditure, increasing government support and initiatives to develop and promote biosimilars,
strategic collaborations to enhance productivity and clinical trial activities for biosimilars.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Diabetes medicine and oncology segments are expected to attain faster growth during the forecast
period
The global biosimilars market is segmented on the basis of product type, manufacturing type,
application, end user and geography.
• On the basis of product type, the global biosimilars market is segmented into:
• Monoclonal Antibodies
• Recombinant Hormones
• Anti-Inflammatory Agents
• Recombinant Growth Stimulators
• Immunomodulators
On the basis of by manufacturing type, the global biosimilars market is segmented into:
• In-house Manufacturing
• Contract Manufacturing Organizations
Request a Customization:
https://www.coherentmarketinsights.com/insight/request-customization/750
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Cost effective potential of biosimilars is the primary factor expected to boost the biosimilars market
in Asia Pacific
Regional segmentation of the biosimilars market by Coherent Market Insights comprises North
America, Europe, Asia-Pacific, Latin America and Middle East and Africa. The first FDA approval
biosimilar in 2015, Sandoz’s Zarxio has marked a promising hit of the biosimilars market across North
America. According to the American Society of Health-System Pharmacists survey in 2013, about 99%
of 214 surveyed pharmacy directors reported at least one oncologic drug shortage with the
consequences of adopting the distribution of biosimilars to meet the rising demands. Also, the
demand for biosimilars is expected to gather momentum in North America owing to the rising
prevalence of cancers, autoimmune diseases, kidney failures and growth hormone deficiency and
increasing approval rates by FDA. The treatment for various diseases including diabetes, rheumatoid
arthritis and types of cancers are anticipated to become affordable in developing countries like China
and India, thus providing opportunities for major players in the Asia Pacific biosimilar market to
expand during the forecast period.
Get Exclusive Discount on this CMI Report:
https://www.coherentmarketinsights.com/insight/request-discount/750
The increase in product extensions integrated with technological innovations is expected to
intensify the competitive environment within manufacturers
Key players operating in the biosimilars market include Sandoz International GmbH, Apotex, Biocon,
Zydus Cadila Healthcare, Celltrion and Pfizer. The leading manufacturers are focusing on outsourcing
the production of biosimilar products with strategic collaborations to replace the existing expensive
drugs. For instance, in August 2016, the FDA approval by Sandoz for the biosimilar Erelzi, used for
treating multiple inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing
spondylitis and juvenile idiopathic arthritis.
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization focused on
assisting its plethora of clients achieve transformational growth by helping them make critical business
decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our
client base includes players from across all business verticals in over 150 countries worldwide. We are
uniquely positioned to help businesses around the globe deliver practical and lasting results through
various recommendations about operational improvements, technologies, emerging market trends and
new working methods. We offer both customized and syndicated market research reports that help our
clients create visionary growth plans to provide traction to their business. We meticulously study
emerging trends across various industries at both the global and regional levels to identify new
opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI
SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry
 Component Providers and System Integrators
 Private and Government organization
 Distributors, Retailors and Value Added Resellers
 Outsourcing Companies
 Healthcare IT Solutions Developers
 Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY
STUDIES
Insights Published
Per Year
GLOBAL
REPORTS
150+
Consulting Projects
Till Date
COUNTRY
ANALYSIS
CONSULT
PROJECTS
125+
Clients Worldwide
Per Year
110+
SURVEY
RESEARCH
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract
Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals,
including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in
order to result in the best possible market research reports across various industries worldwide. Based on our unmatched
expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better
outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure
sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of
opportunities posed therein.
© Coherent market Insights. All Rights Reserved
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702
© Coherent market Insights. All Rights Reserved

Biosimilars are biological medical products which are the identical copies of the original products. Biosimilars are also termed as subsequent entry biologic or follow-on biologic. Biosimilars are expected to possess active properties, similar to that of officially approved original product at present. Biosimilars can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity. In 2010, The Food and Drug Administration (FDA) has gained the authority to approve biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with the existing approved product. Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/750